A complexity of urate transporters

Kidney International

Volumn 78, Issue 5, 2010, Pages 446-452

  Wright, Alan F ^a   Rudan, Igor ^b,c   Hastie, Nicholas D ^a   Campbell, Harry ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF SPLIT   (Croatia)

Author keywords

cardiovascular disease; genetic renal disease; proximal tubule; reactive oxygen species

Indexed keywords

ALLOPURINOL; BENZBROMARONE; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; FEBUXOSTAT; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 9; LOSARTAN; PROBENECID; PROTEIN SLC16A9; PROTEIN SLC17A3; PROTEIN SLC22A11; PROTEIN SLC22A12; PROTEIN SLC2A9; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SODIUM PHOSPHATE COTRANSPORTER 1; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG; URATE; URIC ACID;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; GENE DELETION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GOUT; HUMAN; HYPERURICEMIA; HYPERURICOSURIA; MISSENSE MUTATION; NEPHROLITHIASIS; NEPHRONOPHTHISIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; URIC ACID BLOOD LEVEL; URINE PH;

EID: 77955664254     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.206     Document Type: Review

References (49)

1. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006; 8(Suppl 1): S4.
2. Johnson RJ, Titte S, Cade JR et al. Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25: 3-8.
3. Johnson RJ, Sautin YY, Oliver WJ et al. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol [B] 2009; 179: 67-76.
4. Becker MA. Hyperuricemia and gout. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds). The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill Medical: New York, 2001 pp 2513-2535.
5. Enomoto A, Kimura H, Chairoungdua A et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-452.
6. Li S, Sanna S, Maschio A et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007; 3: e194.
7. Wallace C, Newhouse SJ, Braund P et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008; 82: 139-149.
8. Vitart V, Rudan I, Hayward C et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-442.
9. Doring A, Gieger C, Mehta D et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008; 40: 430-436.
10. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 2001; 18: 247-256.
11. Caulfield MJ, Munroe PB, O'Neill D et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5: e197.
12. Anzai N, Ichida K, Jutabha P et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283: 26834-26838.
13. Matsuo H, Chiba T, Nagamori S et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 2008; 83: 744-751.
14. Bibert S, Hess SK, Firsov D et al. Mouse GLUT9: evidences for a urate uniporter. Am J Physiol Renal Physiol 2009; 297: F612-F619.
15. Cheeseman C. Solute carrier family 2, member 9 and uric acid homeostasis. Curr Opin Nephrol Hypertens 2009; 18: 428-432.
16. Augustin R, Carayannopoulos MO, Dowd LO et al. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004; 279: 16229-16236.
17. Hediger MA, Johnson RJ, Miyazaki H et al. Molecular physiology of urate transport. Physiology (Bethesda) 2005; 20: 125-133.
18. Bannasch D, Safra N, Young A et al. Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog. PLoS Genet 2008; 4: e1000246.
19. Preitner F, Bonny O, Laverriere A et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci USA 2009; 106: 15501-15506.
20. Dehghan A, Kottgen A, Yang Q et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008; 372: 1953-1961.
21. Woodward OM, Kottgen A, Coresh J et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 2009; 106: 10338-10342.
22. Matsuo H, Takada M, Ichida K et al. Common defects of ABCG2, a high capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 2009; 1: 5-11.
23. Kolz M, Johnson T, Sanna S et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5: e1000504.
24. Uchino H, Tamai I, Yamashita K et al. p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem Biophys Res Commun 2000; 270: 254-259. (Pubitemid 30440424)
25. Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol 2007; 19: 151-157.
26. Facchini F, Chen YD, Hollenbeck CB et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-3011.
27. Anzai N, Miyazaki H, Noshiro R et al. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J Biol Chem 2004; 279: 45942-45950.
28. Nieto FJ, Iribarren C, Gross MD et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148: 131-139.
29. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008; 27: 608-619.
30. Sautin YY, Nakagawa T, Zharikov S et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/ nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584-C596.
31. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
32. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521.
33. Martinon F, Petrilli V, Mayor A et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.
34. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-265.
35. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009; 18: 526-530.
36. Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am 2006; 32: 275-293, v-vi.
37. Sheehan NA, Didelez V, Burton PR et al. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 2008; 5: e177.
38. Grundy SM, Brewer Jr HB, Cleeman JI et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
39. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-447.
40. Ford ES, Li C, Cook S et al. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-2532.
41. Nakagawa T, Cirillo P, Sato W et al. The conundrum of hyperuricemia, metabolic syndrome, and renal disease. Intern Emerg Med 2008; 3: 313-318.
42. Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897.
43. Dinour D, Gray NK, Campbell S et al. Renal uric acid absorption defect due to loss-of-function mutations in SLC2A9 causes severe hereditary hypouricemia with exercise-induced acute renal failure. J Am Soc Nephrol 2010; 21: 64-72.
44. Williams SE, Reed AA, Galvanovskis J et al. Uromodulin mutations causing familial juvenile hyperuricaemic nephropathy lead to protein maturation defects and retention in the endoplasmic reticulum. Hum Mol Genet 2009; 18: 2963-2974.
45. Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 2003; 42: 658-676.
46. Law CJ, Maloney PC, Wang DN. Ins and outs of major facilitator superfamily antiporters. Annu Rev Microbiol 2008; 62: 289-305.
47. Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 2009; 61: 1268-1270.
48. Becker MA, Schumacher Jr HR, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461.
49. Ichida K. What lies behind serum urate concentration? Insights from genetic and genomic studies. Genome Med 2009; 1: 118.